Sawai Group Holdings Co Ltd

Chart & Performance

D1W1MN

P/E

19.58

P/S

1.52

EPS

110.48

Div Yield, %

2.12%

Shrs. gr., 5y

0.05%

Rev. gr., 5y

-0.82%

Revenues

176.86b

-11.72%

Net income

13.70b

+8.12%

CFO

23.15b

+77.71%

Dividend

Mar 28, 20250 JPY/sh

Earnings

Feb 12, 2025

Profile

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

URL

https://www.sawaigroup.holdings

IPO date

Apr 01, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	176,862,000 -11.72%	200,344,000 3.37%	193,816,000 3.52%
Cost of revenue	157,976,000	183,957,000	198,267,000
Unusual Expense (Income)
NOPBT	18,886,000	16,387,000	(4,451,000)
NOPBT Margin	10.68%	8.18%
Operating Taxes	5,583,000	3,954,000	5,710,000
Tax Rate	29.56%	24.13%
NOPAT	13,303,000	12,433,000	(10,161,000)
Net income	13,695,000 8.12%	12,667,000 -144.81%	(28,269,000) -329.08%
Dividends	(5,694,000)	(5,693,000)	(5,693,000)
Dividend yield	2.15%	3.55%	2.91%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	16,049,000	13,034,000	13,116,000
Long-term debt	69,699,000	62,590,000	56,404,000
Deferred revenue		2,593,000	3,208,000
Other long-term liabilities	3,198,000	1,490,000	1,435,000
Net debt	50,434,000	32,149,000	14,580,000
Cash flow
Cash from operating activities	23,149,000	13,026,000	34,310,000
CAPEX	(17,915,000)	(27,141,000)	(23,344,000)
Cash from investing activities	(23,112,000)	(27,134,000)	(30,395,000)
Cash from financing activities	2,363,000	(1,267,000)	(11,262,000)
FCF	(6,006,000)	(19,115,000)	(39,141,000)
Balance
Cash	26,535,000	33,255,000	47,863,000
Long term investments	8,779,000	10,220,000	7,077,000
Excess cash	26,470,900	33,457,800	45,249,200
Stockholders' equity	165,034,000	364,380,000	126,413,000
Invested Capital	277,647,100	255,035,200	222,795,800
ROIC	4.99%	5.20%
ROCE	6.20%	5.64%
EV
Common stock shares outstanding	43,924	43,890	43,791
Price	6,030.00 65.21%	3,650.00 -18.16%	4,460.00
Market cap	264,860,484 65.33%	160,198,500 -17.98%	195,307,860
EV	320,663,484	392,795,500	219,903,860
EBITDA	36,941,000	34,070,000	12,594,000
EV/EBITDA	8.68	11.53	17.46
Interest	558,000	407,000	471,000
Interest/NOPBT	2.95%	2.48%